Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: A network meta-analysis of 64 randomized controlled trials and 102 735 patients

European Heart Journal

Volumn 38, Issue 42, 2017, Pages 3160-3172

  D'Ascenzo, Fabrizio ^a   Iannaccone, Mario ^a,b   Saint Hilary, Gaelle ^c   Bertaina, Maurizio ^a   Schulz Schüpke, Stefanie ^d   Lee, Cheol Wahn ^e   Chieffo, Alaide ^f   Helft, Gerard ^g   Gili, Sebastiano ^a,h   Barbero, Umberto ^a   Zoccai, Giuseppe Biondi ^i,j   Moretti, Claudio ^a   Ugo, Fabrizio ^b   D'Amico, Maurizio ^a   Garbo, Roberto ^b   Stone, Gregg ^k   Rettegno, Sara ^a   Omedè, Pierluigi ^a   Conrotto, Federico ^a   Templin, Christian ^h   Colombo, Antonio ^f   Park, Seung Jung ^e   Kastrati, Adnan ^d   Hildick Smith, David ^l   Gasparini, Mauro ^c   Gaita, Fiorenzo ^a   more..

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c POLITECNICO DI TORINO   (Italy)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e University of Ulsan College of Medicine   (South Korea)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j IRCCS NEUROMED   (Italy)

^k Department of Medicine   (United States)

^l Sussex Cardiac Centre   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

BIODEGRADABLE IMPLANT; BLEEDING; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; NETWORK META-ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MYOCARDIAL ISCHEMIA; NETWORK META-ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85040810144     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx437     Document Type: Article

References (31)

1. Warren J, Mehran R, Baber U, Xu K, Giacoppo D, Gersh B, Guagliumi G, Witzenbichler B, Magnus Ohman E, Pocock SJ, Stone GW. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J 2016; 171:40-47.
2. D'Ascenzo F, Iannaccone M, Giordana F, Chieffo A, Connor SO, Napp LC, Chandran S, de la Torre Hernandez JM, Chen SL, Varbella F, Omedè P, Taha S, Meliga E, Kawamoto H, Montefusco A, Chong M, Garot P, Sin L, Gasparetto V, Abdirashid M, Cerrato E, Biondi-Zoccai G, Gaita F, Escaned J, Hildick-Smith D, Lefèvre T, Colombo A, Sheiban I, Moretti C. Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: a propensity matched analysis. IntJ Cardiol 2016; 211:37-42.
3. Moretti C, D'Ascenzo F, Quadri G, Omedè P, Montefusco A, Taha S, Cerrato E, Colaci C, Chen SL, Biondi-Zoccai G, Gaita F. Management of multivessel coronary disease in STEMI patients: a systematic review and meta-analysis. IntJ Cardiol 2015; 179:552-557.
4. Binder RK, Lüscher TF. Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding? Eur Heart J 2015; 36:1207-1211.
5. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379:1393-1402.
6. Lemos PA, Chandwani P, Saxena S, Ramachandran PK, Abhyankar A, Campos CM, Marchini JF, Galon MZ, Verma P, Sandhu MS, Parikh N, Bhupali A, Jain S, Prajapati J. Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. BMJ Open 2016; 6:e010028.
7. Biscaglia S, Ugo F, Ielasi A, Secco GG, Durante A, D'Ascenzo F, Cerrato E, Balghith M, Pasquetto G, Penzo C, Fineschi M, Bonechi F, Templin C, Menozzi M, Aquilina M, Rognoni A, Capasso P, Di Mario C, Brugaletta S, Campo G. Bioresorbable scaffold vs. second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). IntJ Cardiol 2016; 208:40-45.
8. Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW3. Year outcomes with the absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 2016; 387:1277-1289.
9. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385:2371-2382.
10. D'Ascenzo F, Taha S, Moretti C, Omedè P, Grossomarra W, Persson J, Lamberts M, Dewilde W, Rubboli A, Fernandez S, Cerrato E, Meynet I, Ballocca F, Barbero U, Quadri G, Giordana F, Conrotto F, Capodanno D, DiNicolantonio J, Bangalore S, Reed M, Meier P, Zoccai G, Gaita F. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol 2015; 115:1185-1193.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 1896-1900.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
14. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.
15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
16. Kang SH, Chae IH, Park JJ, Lee HS, Kang DY, Hwang SS, Youn TJ, Kim HS. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. JACC Cardiovasc Interv 2016; 9:1203-1212.
17. Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Mariani A, Della Riva D, Genereux P, Leon MB, Bhatt DL, Bendetto U, Rapezzi C, Stone GW. Short-versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 2015; 65:1092-1102.
18. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma SK, Pocock SJ, Dangas GD. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015; 65:1298-1310.
19. Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015; 350: h1618.
20. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur HeartJ 2016; 37:390-399.
21. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'gara PT, Sabatine MS, Smith PK, Smith SC Jr, Focused Update Writing Group. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Thorac Cardiovasc Surg 2016; 152:1243-1275.
22. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315:1735-1749.
23. Thukkani AK, Agrawal K, Prince L, Smoot KJ, Dufour AB, Cho K, Gagnon DR, Sokolovskaya G, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Longterm outcomes in patients with diabetes mellitus related to prolonging clopidogrel more than 12 months After coronary stenting. J Am Coll Cardiol 2015; 66: 1091-1101.
24. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389:1025-1034.
25. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2015; 65:2496-2507.
26. Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Bacchi Reggiani L, Kaiser C, Kim HS, De Waha A, Ribichini F, Stone GW. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5:357-364.
27. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrié D, Piek JJ, Van Boven AJ, Dominici M, Dudek D, McClean D, Helqvist S, Haude M, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Sabaté M, Windecker S, Onuma Y. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimuseluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 2016; 388:2479-2491.
28. Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RY, Koch KT, Baan J Jr, Vis MM, de Winter RJ, Piek JJ, Tijssen JG, Henriques JP, AIDA Investigators. Bioresorbable Scaffolds versus metallic stents in routine PCI. N Engl J Med 2017; 376:2319-2328.
29. Ellis SG, Kereiakes DJ, Stone GW. Everolimus-eluting bioresorbable bascular scaffolds in patients with coronary artery disease: ABSORB III trial 2-years results. American College of Cardiology 2017 Scientific Sessions, 17-19 March 2017. Washington DC, USA.
30. Yamaji K, Räber L, Windecker S. What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion? Euro Intervention 2017; 12:1684-1687.
31. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017; 38:1034-1043.